Rigel Pharmaceuticals, Inc. (RIGL) SEC Filings & Earnings Calls

GAVRETO sales declined 10% YoY, indicating potential competitive pressure or market contraction.

“GAVRETO net product sales were $10.7 million, a decrease of 10% compared to $11.8 million in the same period of 2025.” · word for word

VEPPANU in-license requires significant upfront payment ($70M) and integration risk; commercial success uncertain.

“Rigel paid the upfront payment of $70.0 million to Arvinas and Pfizer in the second quarter.” · word for word

Generic competition for TAVALISSE

“In the longer term, we may eventually face competition from potential manufacturers of generic versions of our marketed products, including the proposed generic version of TAVALISSE” · word for word

Lilly partnership termination

“On April 16, 2026, we received a written notice from Lilly of its decision to terminate the Lilly Agreement, which became effective June 15, 2026.” · word for word

No immediate risk; typical executive turnover.

Execution risk in commercializing VEPPANU; milestone obligations could strain finances if sales targets not met.

“Up to $320M in milestones and tiered royalties; Rigel responsible for development and commercialization.”

Dilution risk from increased share reserves, though typical for biotech compensation.

“Additional shares authorized for equity plans.”

Execution risk in commercializing VEPPANU; milestone obligations could strain finances if sales targets not met.

“Up to $320M in milestones and tiered royalties; Rigel responsible for development and commercialization.”

Eli Lilly collaboration termination for ocadusertib eliminates potential future milestones and royalties

“Rigel received notification from Eli Lilly and Company that it will terminate the collaboration agreement with Rigel, which included the development of ocadusertib... The termination will become effective on June 15, 2026.” · word for word

Increased debt from new revolving credit facility draw of $8M after repaying $40M term loan

“Rigel repaid the remaining outstanding term loan balance of $40.0 million and drew down $8.0 million on the new revolving credit facility.” · word for word

Lilly collaboration termination eliminates future milestones and royalties

“Following termination of the Lilly Agreement, including the prior termination of the CNS disease program effective in November 2025, we do not expect to receive future milestones or royalties under the Lilly Agreement.” · word for word

Generic competition for TAVALISSE could materially reduce revenue

“In the longer term, we may eventually face competition from potential manufacturers of generic versions of our marketed products, including the proposed generic version of TAVALISSE, which, if approved and allowed to enter the market, could result in significant decreases in the revenue derived from the sale of TAVALISSE and thereby materially harm our busin” · word for word

Pipeline concentration risk increases as a major partnered program is terminated; Rigel must now fund development independently or find new partner.

“Termination of Lilly agreement; Rigel evaluating impact.”

Elevated share plan overhang relative to peers

“While our share plan overhang remains elevated relative to peers, it has remained generally consistent year-over-year and has recently been declining.” · word for word

Generic competition for TAVALISSE

“Under the terms of the settlement agreement, Annora will have a license to sell its generic product in second quarter of 2032 or earlier under certain circumstances.” · word for word

Dependence on key commercial products

“Our success depends on attracting and retaining highly skilled executive, scientific, clinical, regulatory, commercial, and operational leaders in a competitive labor market” · word for word

Drug Pricing Pressure

“Enacted or future legislation, and/or potentially unfavorable pricing regulations or other healthcare reform initiatives, may increase the difficulty and cost for us to obtain regulatory approval of our product candidates and/or commercialize our products or our product candidates, once approved, and affect the prices we may set or obtain.” · word for word

Generic Competition Risk

“Under the terms of the settlement agreement, Annora will have a license to sell its generic product in the second quarter of 2032 or earlier under certain circumstances.” · word for word

Clinical Trial Failure Risk

“the progress and success of our clinical trials and preclinical activities (including studies and manufacture of materials) of our product candidates conducted by us” · word for word

Guidance implies total revenue decline from 2025 actual $294.3M to 2026 midpoint $282.5M, despite product sales growth; contract revenue likely declining.

“2026 total revenue guidance $275-290M vs 2025 actual $294.3M”

Dependence on R289 pipeline success; Phase 1b data not until end of 2026.

“R289 dose expansion enrollment ongoing; preliminary data by end of 2026”

Preliminary results subject to audit adjustment

“The above information is preliminary, has not been audited, and is subject to change upon the audit of Rigel’s financial statements for the fourth quarter and year ended December 31, 2025.” · word for word

Lilly terminated CNS disease program collaboration, effective 60 days post-notification

“Lilly will terminate the central nervous system (CNS) disease program related to the collaboration”

Generic competition for TAVALISSE

“Under the terms of the settlement agreement, Annora will have a license to sell its generic product in the second quarter of 2032 or earlier under certain circumstances.” · word for word

Lilly CNS program termination

“On October 1, 2025, we received a notice from Lilly of its intent to terminate the CNS disease program under the Lilly Agreement, which will become effective sixty (60) days following notification.” · word for word

Debt repayment obligation

“As of September 30, 2025, the outstanding principal amount of the loan was $60.0 million, of which $30.0 million principal payments are due within 12 months.” · word for word

Concentration of revenue in few customers

“McKesson Corporation 48% of total revenues for Q3 2025; Cencora 23%; Optime Care 11%; Cardinal Health 10%”